These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 21795432)
1. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Altomare I; Bendell JC; Bullock KE; Uronis HE; Morse MA; Hsu SD; Zafar SY; Blobe GC; Pang H; Honeycutt W; Sutton L; Hurwitz HI Oncologist; 2011; 16(8):1131-7. PubMed ID: 21795432 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Rangwala F; Bendell JC; Kozloff MF; Arrowood CC; Dellinger A; Meadows J; Tourt-Uhlig S; Murphy J; Meadows KL; Starr A; Broderick S; Brady JC; Cushman SM; Morse MA; Uronis HE; Hsu SD; Zafar SY; Wallace J; Starodub AN; Strickler JH; Pang H; Nixon AB; Hurwitz HI Invest New Drugs; 2014 Aug; 32(4):700-9. PubMed ID: 24711126 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Vlahovic G; Meadows KL; Uronis HE; Morse MA; Blobe GC; Riedel RF; Zafar SY; Alvarez-Secord A; Gockerman J; Starodub AN; Ready NE; Anderson EL; Bendell JC; Hurwitz HI Cancer Chemother Pharmacol; 2012 Jul; 70(1):95-102. PubMed ID: 22638798 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Harshman LC; Barbeau S; McMillian A; Srinivas S Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Ng K; Tabernero J; Hwang J; Bajetta E; Sharma S; Del Prete SA; Arrowsmith ER; Ryan DP; Sedova M; Jin J; Malek K; Fuchs CS Clin Cancer Res; 2013 Jul; 19(14):3987-95. PubMed ID: 23743569 [TBL] [Abstract][Full Text] [Related]
8. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684 [TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747 [TBL] [Abstract][Full Text] [Related]
10. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Bullock KE; Petros WP; Younis I; Uronis HE; Morse MA; Blobe GC; Zafar SY; Gockerman JP; Lager JJ; Truax R; Meadows KL; Howard LA; O'Neill MM; Broadwater G; Hurwitz HI; Bendell JC Cancer Chemother Pharmacol; 2011 Feb; 67(2):465-74. PubMed ID: 21079958 [TBL] [Abstract][Full Text] [Related]
11. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Tappenden P; Jones R; Paisley S; Carroll C Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499 [TBL] [Abstract][Full Text] [Related]
12. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Moroney J; Fu S; Moulder S; Falchook G; Helgason T; Levenback C; Hong D; Naing A; Wheler J; Kurzrock R Clin Cancer Res; 2012 Oct; 18(20):5796-805. PubMed ID: 22927482 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Guan ZZ; Xu JM; Luo RC; Feng FY; Wang LW; Shen L; Yu SY; Ba Y; Liang J; Wang D; Qin SK; Wang JJ; He J; Qi C; Xu RH Chin J Cancer; 2011 Oct; 30(10):682-9. PubMed ID: 21959045 [TBL] [Abstract][Full Text] [Related]
14. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358 [TBL] [Abstract][Full Text] [Related]
15. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604 [TBL] [Abstract][Full Text] [Related]
17. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E; Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633 [TBL] [Abstract][Full Text] [Related]
18. Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. Liang HL; Hu AP; Li SL; Liu JY Med Oncol; 2014 Jun; 31(6):976. PubMed ID: 24793617 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353 [TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Yildiz R; Buyukberber S; Uner A; Yamac D; Coskun U; Kaya AO; Ozturk B; Yaman E; Benekli M Cancer Invest; 2010 Jan; 28(1):33-7. PubMed ID: 19995229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]